Replimune Group (Nasdaq:REPL) - Hisse Senedi Fiyatı, Haberler ve Analizler

REPL Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan Replimune Group, Inc. kanseri tedavi etmek için onkolitik immünoterapilerin geliştirilmesine odaklanmaktadır. Daha fazla detay

REPL temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 45.6% daha düşük bir oranda işlem görüyor

Gelirin yılda 57.42% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

Son 3 ayda dalgalı hisse senedi fiyatı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Replimune Group, Inc. Rakipler

Autolus Therapeutics

NasdaqGS:AUTL

US$823.6m

Anavex Life Sciences

NasdaqGS:AVXL

US$766.1m

Relay Therapeutics

NasdaqGM:RLAY

US$796.7m

Prothena

NasdaqGS:PRTA

US$838.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Replimune Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$14.05
52 Haftanın En Yüksek Seviyesi	US$17.00
52 Haftanın En Düşük Seviyesi	US$4.92
Beta	1.19
11 Aylık Değişim	16.60%
3 Aylık Değişim	27.03%
1 Yıllık Değişim	24.12%
33 Yıllık Değişim	-49.84%
5 Yıllık Değişim	3.69%
Halka arzdan bu yana değişim	-7.32%

Son Haberler & Güncellemeler

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Nov 23

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

Hissedar Getirileri

	REPL	US Biotechs	US Pazar
7D	25.1%	4.0%	2.0%
1Y	24.1%	18.0%	32.4%

Getiri vs. Endüstri: REPL geçen yıl % 18 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: REPL geçen yıl % 32.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is REPL's price volatile compared to industry and market?
REPL volatility
REPL Average Weekly Movement	13.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: REPL hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: REPL 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	331	Sush Patel	www.replimune.com

Klinik aşamada bir biyoteknoloji şirketi olan Replimune Group, Inc. kanseri tedavi etmek için onkolitik immünoterapilerin geliştirilmesine odaklanmaktadır. Şirketin tescilli tümöre yönelik onkolitik immünoterapi ürün adayları, kansere karşı bağışıklık sistemini aktive etmek üzere tasarlanmış ve amaçlanmıştır. Şirketin öncü ürün adayı, GALV-GP R(-) ve insan GM-CSF'sini ifade eden HSV-1'in seçici olarak çoğalan bir versiyonu olan ve çeşitli solid tümörler için Faz I/II klinik çalışmalarında bulunan RP1'dir.

Replimune Group, Inc. Temel Bilgiler Özeti

Replimune Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
REPL temel i̇stati̇sti̇kler
Piyasa değeri	US$983.84m
Kazançlar(TTM)	-US$213.02m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-4.5x

F/K Oranı

REPL aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
REPL gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$213.02m
Kazançlar	-US$213.02m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.11
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	11.9%

REPL uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

REPL Stoklara Genel Bakış

Ödüller

Risk Analizi

Replimune Group, Inc. Rakipler

NasdaqGS:AUTL

US$823.6m

NasdaqGS:AVXL

US$766.1m

NasdaqGM:RLAY

US$796.7m

NasdaqGS:PRTA

US$838.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Recent updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis